Navigation Links
Biomarker Challenges in Biosimilar Drug Development, New Life Science Webinar Hosted by Xtalks
Date:10/29/2013

Toronto, Canada (PRWEB) October 29, 2013

Biologics have transformed the way several diseases have been traditionally treated and managed over the past several years. Therapeutic antibodies are a class of biologics that has been exceptionally effective in the treatment of life threatening diseases such as cancer and inflammatory diseases.

As patents and exclusivity on several originator biologics are expiring, the industry has been moving in to generate biosimilars. Biosimilars are products that are highly similar to the originator molecules with no clinically meaningful differences in safety, purity and potency.

Owing to the complexity of biological molecules and the variability of sophisticated modern processes by which they are generated, it is extremely difficult to generate fully identical biosimilars. Subtle structural and functional differences can lead to potentially serious consequences when administered into the diseased host. Regulatory agencies require the generation of physicochemical, structural and functional data on candidate biosimilars prior to approval for use in human subjects. Thus, successful development of biosimilars requires the demonstration of pharmacological similarity with the originator biologics.

This webinar focuses on Covance's experience with in vitro assays to demonstrate pharmacological similarity between biologics and biosimilars.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit http://xtalks.com/biomarkers-biosimilar-drug-development.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11267149.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biomarkers Market to Grow at a CAGR of 18.5% to 2018 in a New Research Report at RnRMarketResearch.com
2. LC/MS Biomarker Assay Validation Strategies Using Surrogate Matrix and Surrogate Analyte Approaches, New Life Science Webinar Hosted by Xtalks
3. Biomarkers Market worth $40.8 Billion by 2018
4. Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
5. Biomarkers: Technological and Commercial Outlook 2013-2023
6. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
7. Optimizing Assays from FFPE for Biomarker Strategies, New Life Science Webinar Hosted by Xtalks
8. Biomarkers predict time to ovarian cancer recurrence
9. Epigenetic and MicroRNA Biomarkers 2013 Market Report
10. Biomarkers - Technologies, Markets and Companies - Updated 2012 Report
11. Molecular Biomarkers for Cancer Detection and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a variety of fracture-specific plating options designed to address fractures of the distal ... fixation solutions. , The Acumed Ankle Plating System 3 is composed of seven ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say ... mesothelioma may be hampering the research that could lead to one good one. Surviving ... read it now. , The team evaluated 98 mesothelioma patients who ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven ... Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for ... designation granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating ...
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
Breaking Biology Technology:
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
Breaking Biology News(10 mins):